News

Public · Published

Karyopharm Therapeutics Inc. expected to post a loss of 95 cents a share - Earnings Preview

Karyopharm Therapeutics Inc. is expected to report a 23.8% drop in quarterly revenue to $33.548 million, down from $44.04 million a year earlier, when it reports results on November 2 for the period ending September 30, 2026. Analysts expect a loss of 95 cents a share.

Published:

Updated:

What happened

Karyopharm Therapeutics Inc. is expected to report a 23.8% drop in quarterly revenue to $33.548 million, down from $44.04 million a year earlier, when it reports results on November 2 for the period ending September 30, 2026. Analysts expect a loss of 95 cents a share.

Confirmed

Global impact / market context

A falling revenue estimate means the company is expected to take in less money from sales, which can make it harder to cover costs and move toward profit. The expected loss of 95 cents a share shows analysts still see the company spending more than it earns.

Analyst inference

Analysts rate the stock a buy on average, with four buy ratings and one hold, and their median 12-month price target is $7.50, far above the $0.88 last close. That gap implies the market currently prices the shares well below analyst targets.

Analyst inference

What to watch

  1. Watch whether the actual revenue reported on November 2 lands near the $33.548 million mean estimate from five analysts, which would confirm or break the expected 23.8% decline from a year earlier. Confirmed
  2. Watch whether actual loss per share matches the 95-cent estimate, since recent quarters mostly missed, including a larger-than-expected loss last quarter, which is worse than analysts had forecast. Analyst inference
  3. Watch whether the mean earnings estimate of analysts stays unchanged in the last three months, as that stability suggests no new company news has shifted analyst views on costs or sales. Analyst inference

Evidence

  • Original source link unavailable